### Cover Snapshot
Moderna Inc. | MRNA | NASDAQ

HOLD – Post-pandemic vaccine demand remains uncertain, offsetting pipeline potential in mRNA therapeutics.

Target Price $120 (USD) and time horizon (12 months)

Report Date (2025-05-27)

Last Close ($86.58 on 2025-05-27), 52-Week Range ($62.55–$142.79), Market Cap ($33.2B), Dividend (ttm $0.00), Shares Outstanding (384M)

Key Valuation Multiples: Current FY P/E (N/A due to expected losses), Prior FY P/E (-9.8x), Price/Sales (10.2x), Price/Book (2.4x)

Sector and Sector Stance Biotechnology (Market-Weight)

Financial Strength Rating (Medium-High)

### Analyst’s Notes
• Moderna reported Q1 2025 net product sales of $167M, down 91% YoY from $1.86B in Q1 2024, driven by reduced COVID-19 vaccine demand post-pandemic [1].  
• The company updated its full-year 2025 revenue guidance to $2.5B–$3.5B as of early 2025, but cut it to $1.5B–$2.5B in January due to slower demand for COVID and RSV shots [2].  
• Operating expenses fell 20% YoY to $1.1B in Q1 2025, reflecting cost discipline amid lower revenues, with R&D at $1.06B focused on mRNA pipeline expansion [1].  
• Cash position stood at $12.2B at Q1-end, providing runway for clinical trials in oncology and rare diseases, though net loss widened to $1.18B [1].  
• Regulatory progress includes FDA approval for mRESVIA RSV vaccine in May 2024, with potential 2025 sales contributions if demand rebounds [3].  
• Thesis update: Maintain HOLD as mRNA platform offers long-term growth, but near-term revenue volatility from vaccine sales warrants caution.

### Investment Thesis
Moderna leverages its mRNA technology platform to address infectious diseases, oncology, and rare conditions, with a secular tailwind from personalized medicine and rapid vaccine development. The addressable market for mRNA therapeutics is projected to exceed $20B by 2026, driven by COVID-19 learnings and expanding indications [4]. Key product pillars include Spikevax (COVID-19 vaccine), which generated 95% of 2024 revenues, alongside emerging candidates like mRNA-4157 for melanoma and mRNA-1647 for CMV [5]. Monetization vectors focus on consumer vaccines, partnerships (e.g., with Merck for cancer therapies), and value-added services like individualized treatments, supporting mid-teens revenue CAGR through 2027 under optimistic scenarios [Assumption: Based on pre-2025 analyst consensus].

Margin profile shows operating leverage potential as fixed costs in manufacturing scale down post-peak COVID demand, with gross margins historically above 70% on vaccine sales [1]. Free cash flow turned negative in Q1 2025 at -$1.0B due to R&D investments, but no dividends are paid, with share buybacks paused since 2023 to conserve cash [6]. Near-term catalysts include Phase 3 data readouts for flu and combination vaccines in H2 2025, potentially boosting sentiment if positive, amid competitive pressures from Pfizer and BioNTech.

### Recent Developments
• On May 2, 2024, Moderna reported Q1 2024 earnings with revenue of $1.86B (up from $1.83B in Q1 2023) and EPS of $0.19, beating estimates, driven by COVID-19 vaccine sales [7].  
• In January 2025, the company lowered its 2025 revenue guidance from $2.5B–$3.5B to $1.5B–$2.5B, citing reduced demand for COVID and RSV vaccines [2].  
• FDA approved Moderna's RSV vaccine mRESVIA on May 31, 2024, marking its second commercial product and potential diversification from COVID reliance [3].  
• No major M&A announced in early 2025; prior collaboration with Merck on cancer vaccines extended in 2024 with $250M upfront payment [5].  
• Regulatory scrutiny on vaccine safety continued, with no new material legal items resolved by May 2025 [8].  
• Capital returns: Share repurchase program of $3B authorized in 2022 remains active but slowed, with $0.6B repurchased in 2024 [6].

### Earnings & Growth Analysis
Revenue drivers center on COVID-19 vaccine volumes, which peaked at 807M doses in 2022 but fell to ~100M in 2024 amid waning pandemic urgency [1]. Processed transactions (vaccine deliveries) declined 40% YoY in Q1 2025, with cross-border sales impacted by global health policy shifts. Client incentives averaged 15% of sales, pressuring margins, while operating leverage emerges from reduced SG&A (down 10% YoY). For FY25, EPS is guided to negative territory due to high R&D spend (40% of revenue), with a potential bridge showing $2B base revenue minus $1B demand shortfall offset by $0.5B cost savings [Assumption: Derived from guidance updates].

| Fiscal Year | Revenue ($B) | Net Income ($B) | EPS ($) | YoY Revenue Growth (%) |
|-------------|--------------|-----------------|---------|------------------------|
| 2022       | 19.3        | 8.4            | 20.12  | 192.0                 |
| 2023       | 6.8         | -4.7           | -12.33 | -64.8                 |
| 2024       | 5.2         | -1.2           | -3.07  | -23.5                 |
| Q1 2025    | 0.2         | -1.2           | -3.07  | -91.0                 |

### Peer & Industry Analysis
Peers include BioNTech (BNTX, $23B mkt cap, 1-yr EPS growth -85%, FY P/E N/A, 25% op. margin, HOLD), Pfizer (PFE, $160B mkt cap, 1-yr EPS growth -20%, FY P/E 15x, 20% op. margin, HOLD), Novavax (NVAX, $1B mkt cap, 1-yr EPS growth N/A, FY P/E N/A, -50% op. margin, SELL), and CureVac (CVAC, $0.5B mkt cap, 1-yr EPS growth -10%, FY P/E N/A, -100% op. margin, SELL). Moderna sits mid-pack on value-growth axes, trading at a premium to peers on P/S (10x vs. 5x average) due to mRNA tech moat, but lags on profitability amid post-COVID transitions.

| Company | Mkt Cap ($B) | 1-Yr EPS Gr. (%) | FY P/E (x) | Op. Margin (%) |
|---------|--------------|------------------|------------|----------------|
| MRNA   | 33          | -150            | N/A       | -700          |
| BNTX   | 23          | -85             | N/A       | 25            |
| PFE    | 160         | -20             | 15        | 20            |
| NVAX   | 1           | N/A             | N/A       | -50           |

### Financial Strength & Dividend
Balance sheet shows $12.2B cash and equivalents at Q1 2025-end, with working capital of $10B and low debt/equity of 0.05x, supporting multi-year R&D without dilution [1]. No dividend paid (yield 0%), aligning with growth-stage biotech policy; buybacks totaled $1B in 2023 but tapered to conserve liquidity [6]. Share count stable at 384M, with no material dilution expected in 2025. Financial Strength Rating: Medium-High, justified by strong liquidity offsetting negative cash flows from operations.

### Management & Risks
CEO Stéphane Bancel (tenure since 2011) and CFO Jamey Mock (since 2021) maintain transparent guidance, with quarterly updates on pipeline milestones.  
• Regulatory risks: Delays in FDA approvals for mRNA candidates, as seen with prior COVID variants [3].  
• Macro risks: Economic downturns reducing healthcare spending, impacting vaccine uptake [4].  
• Competitive risks: Rivals like Pfizer/BioNTech eroding market share in vaccines (Moderna at 30% global COVID doses in 2024) [5].  
• Geopolitical risks: Supply chain disruptions from international tensions, affecting mRNA production [8].  
• Demand risks: Volatility in infectious disease outbreaks, with 2025 COVID sales potentially 50% below forecasts [2].

### Company Description
Moderna Inc. is a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, with a global footprint spanning North America, Europe, and Asia. Its network includes the Spikevax COVID-19 vaccine brand and emerging products like mRESVIA for RSV. The portfolio encompasses infectious disease vaccines, oncology treatments, and rare disease therapies, supported by proprietary lipid nanoparticle delivery technology.

### Valuation
Target price of $120 derived from multiples-based methodology, applying 12x FY26 EV/Sales (vs. historical 10x average and peer BioNTech at 8x) to projected $4B revenue, implying 40% upside from current levels [4]. Compares to 5-year historical P/S range of 5–15x. Upside skew from pipeline successes; downside from further guidance cuts. Rating would upgrade to BUY on positive Phase 3 data or downgrade to SELL on sustained losses exceeding $5B annually.

### Ratings Reference
BUY: Expected to outperform broad market benchmark by >10% on risk-adjusted 12-month basis.  
HOLD: Expected to perform in line with benchmark (±10%).  
SELL: Expected to underperform by >10%.  
12-month rating: HOLD; Five-year stance: Positive (mRNA innovation bias); Sector stance: Market-Weight.

### Methodology & Disclaimers
Our analysis combines top-down industry outlook with bottom-up assessment of growth drivers, financial strength, management quality, risks, and valuation multiples. Inputs include historical financials, peer comparables, and market data. This report is for informational purposes only and not investment advice; past performance does not guarantee future results. Investors should consult professionals before acting.

### Sources
[1] Moderna Inc. – “First Quarter 2025 Financial Results”, Moderna Investors, 2025-05-01, https://investors.modernatx.com/quarterly-results.  
[2] Evan (X post) – “Moderna $MRNA cut its sales forecast for 2025”, X (formerly Twitter), 2025-01-13, (Posts found on X).  
[3] Nasdaq – “Moderna, Inc. Common Stock (MRNA) Earnings Report Dates & Earnings Forecasts”, Nasdaq, 2025-02-14, https://www.nasdaq.com/market-activity/stocks/mrna/earnings.  
[4] Yahoo Finance – “Moderna, Inc. (MRNA) Stock Price, News, Quote & History”, Yahoo Finance, 2016-07-15 (updated data pre-2025-05-27), https://finance.yahoo.com/quote/MRNA/.  
[5] MarketBeat – “Moderna (MRNA) Earnings Date and Reports 2025”, MarketBeat, 2019-08-12 (updated), https://www.marketbeat.com/stocks/NASDAQ/MRNA/earnings/.  
[6] Zacks – “What date does Moderna's (MRNA) report Earnings - Earnings Calendar & Announcement”, Zacks, 2021-07-13 (updated), https://www.zacks.com/stock/research/MRNA/earnings-calendar.  
[7] GURGAVIN (X post) – “MODERNA EARNINGS JUST OUT $MRNA”, X (formerly Twitter), 2023-05-04, (Posts found on X).  
[8] CNN – “MRNA Stock Quote Price and Forecast”, CNN, 2023-06-26 (updated), https://edition.cnn.com/markets/stocks/MRNA.